ASH: With survival win against J&J's Darzalex, GSK bolsters case for return of myeloma ADC Blenrep

GSK’s antibody-drug conjugate Blenrep has mounted a sizable patient survival benefit among certain multiple myeloma patients in a head-to-head comparison against Johnson & Johnson’s industry-leading Darzalex.